From the 4th until the 8th of December : join our free social media event taking place at each Full Moon – via #EAv – and give a boost to your social networking!
The Full Cold Moon
There are native American names for the full moons that you can find here, here or here.
December’s full moon got its name from the fact that during December the cold weather really began to hit the tribes hard. Additionally, the nights were long and dark which only seemed to intensify the chilling temperatures. This full Moon is also called the Long Nights Moon by some Native American tribes as the winter nights lengthen.
#FullMoonEngageMe Social Media Event N°8 Schedule
The event will start on Thursday 4th of December at 19:00 UTC and will last until Monday the 08th in HERE.
Please read our FAQs and use the comment section to ask any question about the event.
You can join – for FREE – Empire Avenue at anytime – before and after any FullMoon EngageMe Social Media Event.
You can use this link – with no strings attached – to get some extra “eaves” at start !
See you soon 😉
Children With Attention Deficits Concentrate Better After Walk in the Park
In a 2004 study, children with Attention-Deficit/Hyperactivity Disorder had fewer symptoms when activities were carried out in a green or natural outdoor setting such as parks, woods, farms, etc., than they did when in outdoor human-built settings or in indoor settings.
Nature, or what in recent years has been referred to as vitamin N, may be one of the answers as treatment for ADHD…
We examined the impact of relatively “green” or natural settings on attention-deficit/hyperactivity disorder (ADHD) symptoms across diverse subpopulations of children.
Parents nationwide rated the aftereffects of 49 common after-school and weekend activities on children’s symptoms. Aftereffects were compared for activities conducted in green outdoor settings versus those conducted in both built outdoor and indoor settings.
In this national, nonprobability sample, green outdoor activities reduced symptoms significantly more than did activities conducted in other settings, even when activities were matched across settings. Findings were consistent across age, gender, and income groups; community types; geographic regions; and diagnoses.
Green outdoor settings appear to reduce ADHD symptoms in children across a wide range of individual, residential, and case characteristics.
Advances in Steroid Biochemistry and Molecular Biology, 2006
Glucocorticoids play an essential role in the regulation of key physiological processes, including immunomodulation, brain function, energy metabolism, electrolyte balance and blood pressure. Exposure to naturally occurring compounds or industrial chemicals that impair glucocorticoid action may contribute to the increasing incidence of cognitive deficits, immune disorders and metabolic diseases. Potentially, “glucocorticoid disruptors” can interfere with various steps of hormone action, e.g. hormone synthesis, binding to plasma proteins, delivery to target cells, pre-receptor regulation of the ratio of active versus inactive hormones, glucocorticoid receptor (GR) function, or export and degradation of glucocorticoids. Several recent studies indicate that such chemicals exist and that some of them can cause multiple toxic effects by interfering with different steps of hormone action. For example, increasing evidence suggests that organotins disturb glucocorticoid action by altering the function of factors that regulate the expression of 11beta-hydroxysteroid dehydrogenase (11beta-HSD) pre-receptor enzymes, by direct inhibition of 11beta-HSD2-dependent inactivation of glucocorticoids, and by blocking GR activation. These observations emphasize on the complexity of the toxic effects caused by such compounds and on the need of suitable test systems to assess their effects on each relevant step.
Sources and more information
Disruption of glucocorticoid action by environmental chemicals: potential mechanisms and relevance, NCBI PMID: 17045799, 2006 Dec;102(1-5):222-31. Epub 2006 Oct 12.
Full text link, The Journal of Steroid Biochemistry and Molecular Biology, pii/S0960076006002512, doi:10.1016/j.jsbmb.2006.09.010.
By the Collaborative on Health and the Environment
Retha Newbold discussed the program called The Consortium Linking Academic and Regulatory Insights on the Toxicity of Bisphenol A (CLARITY-BPA).
On this call Retha Newbold, MS, Researcher Emeritus, National Toxicology Program, National Institute of Environmental Health Sciences, discussed the program called “The Consortium Linking Academic and Regulatory Insights on the Toxicity of Bisphenol A (CLARITY-BPA)” which is an interagency agreement, conducted under the auspices of the National Toxicology Program (NTP), between The National Institute of Environmental Health Sciences (NIEHS) supported grantees, the staff of the Division of the National Toxicology Program (DNTP) at NIH/NIEHS, and the Food and Drug Administration at the National Center for Toxicological Research (FDA/NCTR). The goals of the consortium are to enhance the utility of a perinatal 2-year GLP chronic toxicity study on BPA for regulatory decision-making by incorporating a wide range of doses and some additional disease-related endpoints that are not usually covered.
To this end, 12 NIEHS grantees are studying hypothesis-driven mechanisms by investigating specific endpoints that maybe altered by BPA including behavioral/neuroendocrine, immune function, cardiac, reproductive tract, cancer, thyroid, and other organ systems. This consortium is unique in that it combines the knowledge and skills of the NTP staff with experts from the academic field who are covering more mechanistic studies. Although this program focuses on BPA, it may provide an example of how to better study effects of other endocrine disrupting chemicals especially since numerous organ systems may be involved.
Retha Newbold Speaks About CLARITY-BPA: A Novel Approach to Study Endocrine Disrupting Chemicals, healthandenvironment.org, May 21, 2014.
À l’heure où le public se pose de plus en plus de questions sur l’avenir de notre système de santé et l’augmentation sans cesse croissante de la part des médicaments dans les dépenses de santé, L’envers de la pilule est un ouvrage incontournable.
S’appuyant sur une recherche poussée et possédant une plume alerte, J.-Claude St-Onge, brosse un tableau clair des dessous de l’industrie pharmaceutique. Dans cette synthèse, il dévoile l’envers sombre et alarmant des pratiques de cette industrie et montre comment elle est devenue, au cours des dernières décennies, la plus rentable de toutes. Son analyse porte entre autres sur
les profits colossaux et en constante progression de cet empire financier,
les brevets et le monopole des médicaments,
les essais cliniques,
la recherche et développement,
la médicalisation des événements de la vie ou l’art de forger des pathologies,
les nouveaux médicaments qui n’en sont pas véritablement, trop chers et moins efficaces que les vieilles pilules,
les médicaments dangereux,
les médicaments plus ou moins utiles.
En excellent vulgarisateur, il illustre son -propos d’exemples probants.”À petite dose, on finit par digérer ces faits. Mais, en les mettant bout à bout, la pilule devient difficile à avaler“, estime l’auteur.
US Preventive Services Task Force Final Recommendation Statement
” The U.S. Preventive Services Task Force (USPSTF) found no studies that evaluated the direct benefit of screening for vitamin D deficiency in adults. The USPSTF found adequate evidence that treatment of asymptomatic vitamin D deficiency has no benefit on cancer, type 2 diabetes mellitus, risk for death in community-dwelling adults, and risk for fractures in persons not selected on the basis of being at high risk for fractures. The USPSTF found inadequate evidence on the benefit of treatment of asymptomatic vitamin D deficiency on other outcomes, including psychosocial and physical functioning. Although the evidence is adequate for a few limited outcomes, the overall evidence on the early treatment of asymptomatic, screen-detected vitamin D deficiency in adults to improve overall health outcomes is inadequate. ”
Carl Djerassi thinks that there is not a single pharmaceutical company who will touch a male contraceptive pill – for economic and socio-political, rather than scientific, reasons
” …will there be a male Pill? Never. This has nothing to do with science; we know exactly how to develop them. But there’s not a single pharmaceutical company that will touch this, for economic and socio-political rather than scientific reasons. Their focus is on diseases of a geriatric population: diabetes, obesity, cardiovascular, Alzheimer’s. Male contraception is nothing compared with an anti-obesity drug. Plus, men are preoccupied with the side-effects. Men who start taking it at 18 will ask, ‘Will I still be able to have a child 30 years later?’ How do you answer? To prove that is monstrously difficult and expensive. No one would spend that amount of money… ”